» Articles » PMID: 21487727

PD-1 Polymorphisms Are Associated with Sporadic Breast Cancer in Chinese Han Population of Northeast China

Overview
Specialty Oncology
Date 2011 Apr 14
PMID 21487727
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The programmed death-1 (PD-1) is a potent immunoregulatory molecule which is responsible for the negative regulation of T-cell activation and peripheral tolerance. In order to investigate the association between polymorphisms of PD-1 and breast cancer, a case-control study was conducted in Chinese female population consisting of 490 cases with breast cancer and 512 age-matched healthy individuals from Heilongjiang Province of China. Four polymorphisms of the PD-1 gene, including rs36084323 (PD-1.1), rs7421861, rs2227982 (PD-1.9), and rs2227981 (PD-1.5), were selected and genotypes were determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The frequencies of PD-1.1 GG genotype and PD-1.5 CT genotype were significantly lower in cases compared with controls (P = 0.020 and 0.004, respectively), and PD-1.5 CC genotype and C allele had higher frequencies in cases (P = 0.003 and 0.010). In haplotype analysis, we observed that the frequencies of ATTC and GTCT haplotypes were lower in cases than those of in controls (P = 0.0055 and 0.0012, respectively), whereas the GTCC and ATCC haplotypes had higher frequencies in cases (P = 0.0040 and 0.00008037, respectively). Additionally, strong association was showed between PD-1.1 and P53, and haplotype CCTA was associated with ER status. These results primarily suggest that PD-1 gene polymorphisms may affect the breast cancer risk and prognosis in Chinese Han females of Heilongjiang Province in Northeast China.

Citing Articles

Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.

Yang M, Liu Y, Zheng S, Geng P, He T, Lu L Aging (Albany NY). 2024; 16(7):6068-6097.

PMID: 38546391 PMC: 11042937. DOI: 10.18632/aging.205689.


The PD-1 single-nucleotide polymorphism rs11568821 and rs2227981 as a novel prognosis model in a triple-negative breast cancer patient.

Boguszewska-Byczkiewicz K, Wow T, Szymanska B, Kosny M, Kolacinska-Wow A Mol Biol Rep. 2023; 50(7):6279-6285.

PMID: 37212960 DOI: 10.1007/s11033-023-08423-3.


Rs10204525 Polymorphism of the Programmed Death (PD-1) Gene Is Associated with Increased Risk in a Saudi Arabian Population with Colorectal Cancer.

Al-Harbi N, Vaali-Mohammed M, Al-Omar S, Zubaidi A, Al-Obeed O, Abdulla M Medicina (Kaunas). 2022; 58(10).

PMID: 36295599 PMC: 9607617. DOI: 10.3390/medicina58101439.


Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients.

Kuol N, Yan X, Barriga V, Karakkat J, Vassilaros S, Fyssas I Biomedicines. 2022; 10(8).

PMID: 36009373 PMC: 9405402. DOI: 10.3390/biomedicines10081827.


A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets.

Cai Z, Ang X, Xu Z, Li S, Zhang J, Pei C Transl Cancer Res. 2022; 10(9):3993-4001.

PMID: 35116697 PMC: 8797719. DOI: 10.21037/tcr-21-561.